COVID-19 and metabolic disease: mechanisms and clinical management

Clark, 2020, Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study, Lancet Glob Health, 8, e1003, 10.1016/S2214-109X(20)30264-3 Thakur, 2021, A systematic review and meta-analysis of geographic differences in comorbidities and associated severity and mortality among individuals with COVID-19, Sci Rep, 11, 10.1038/s41598-021-88130-w Apicella, 2020, COVID-19 in people with diabetes: understanding the reasons for worse outcomes, Lancet Diabetes Endocrinol, 8, 782, 10.1016/S2213-8587(20)30238-2 Batabyal, 2021, Metabolic dysfunction and immunometabolism in COVID-19 pathophysiology and therapeutics, Int J Obes, 45, 1163, 10.1038/s41366-021-00804-7 Costa, 2020, Metabolic syndrome and COVID-19: An update on the associated comorbidities and proposed therapies, Diabetes Metab Syndr, 14, 809, 10.1016/j.dsx.2020.06.016 Docherty, 2020, Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study, BMJ, 369 Singh, 2021, Non-alcoholic fatty liver disease and clinical outcomes in patients with COVID-19: a comprehensive systematic review and meta-analysis, Diabetes Metab Syndr, 15, 813, 10.1016/j.dsx.2021.03.019 Singh, 2020, Prevalence of co-morbidities and their association with mortality in patients with COVID-19: a systematic review and meta-analysis, Diabetes Obes Metab, 22, 1915, 10.1111/dom.14124 Stefan, 2021, Global pandemics interconnected – obesity, impaired metabolic health and COVID-19, Nat Rev Endocrinol, 17, 135, 10.1038/s41574-020-00462-1 Kreutmair, 2021, Distinct immunological signatures discriminate severe COVID-19 from non-SARS-CoV-2-driven critical pneumonia, Immunity, 54, 1578, 10.1016/j.immuni.2021.05.002 Kass, 2020, Obesity could shift severe COVID-19 disease to younger ages, Lancet, 395, 1544, 10.1016/S0140-6736(20)31024-2 Bornstein, 2021, Consequences of the COVID-19 pandemic for patients with metabolic diseases, Nat Metab, 3, 289, 10.1038/s42255-021-00358-y Gregory, 2021, COVID-19 severity is tripled in the diabetes community: a prospective analysis of the pandemic's impact in type 1 and type 2 diabetes, Diabetes Care, 44, 526, 10.2337/dc20-2260 Ahmed, 2020, Why inequality could spread COVID-19, Lancet Public Health, 5, e240, 10.1016/S2468-2667(20)30085-2 Simpson, 2020, COVID-19: Obesity, deprivation and death, J Glob Health, 10, 10.7189/jogh.10.020389 Brosh-Nissimov, 2021, BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel, Clin Microbiol Infect, 10.1016/j.cmi.2021.06.036 Maestre-Muñiz, 2021, Long-term outcomes of patients with coronavirus disease 2019 at one year after hospital discharge, J Clin Med, 10, 10.3390/jcm10132945 Ramakrishnan, 2021, Unraveling the mystery surrounding post-acute sequelae of COVID-19, Front Immunol, 12, 10.3389/fimmu.2021.686029 Simões e Silva, 2013, ACE2, angiotensin-(1-7) and Mas receptor axis in inflammation and fibrosis, Br J Pharmacol, 169, 477, 10.1111/bph.12159 Li, 2017, The vasoprotective axes of the renin-angiotensin system: Physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases, Pharmacol Res, 125, 21, 10.1016/j.phrs.2017.06.005 Coto, 2021, The renin-angiotensin-aldosterone system and coronavirus disease 2019, Eur Cardiol, 16, e07, 10.15420/ecr.2020.30 Bornstein, 2020, Practical recommendations for the management of diabetes in patients with COVID-19, Lancet Diabetes Endocrinol, 8, 546, 10.1016/S2213-8587(20)30152-2 Lv, 2017, Effects of taurine on ACE, ACE2 and HSP70 expression of hypothalamic-pituitary-adrenal axis in stress-induced hypertensive rats, Adv Exp Med Biol, 975, 871, 10.1007/978-94-024-1079-2_69 Coate, 2020, SARS-CoV-2 cell entry factors ACE2 and TMPRSS2 are expressed in the microvasculature and ducts of human pancreas but are not enriched in β cells, Cell Metab, 32, 1028, 10.1016/j.cmet.2020.11.006 Kusmartseva, 2020, Expression of SARS-CoV-2 entry factors in the pancreas of normal organ donors and individuals with COVID-19, Cell Metab, 32, 1041, 10.1016/j.cmet.2020.11.005 Liu, 2020, ACE2 expression in pancreas may cause pancreatic damage after SARS-CoV-2 infection, Clin Gastroenterol Hepatol, 18, 2128, 10.1016/j.cgh.2020.04.040 Fignani, 2020, SARS-CoV-2 receptor angiotensin I-converting enzyme type 2 (ACE2) is expressed in human pancreatic β-cells and in the human pancreas microvasculature, Front Endocrinol (Lausanne), 11, 10.3389/fendo.2020.596898 Müller, 2021, SARS-CoV-2 infects and replicates in cells of the human endocrine and exocrine pancreas, Nat Metab, 3, 149, 10.1038/s42255-021-00347-1 Wu, 2021, SARS-CoV-2 infects human pancreatic β cells and elicits β cell impairment, Cell Metab, 33, 1565, 10.1016/j.cmet.2021.05.013 Steenblock, 2021, Viral infiltration of pancreatic islets in patients with COVID-19, Nat Commun, 12, 10.1038/s41467-021-23886-3 Kumar, 2020, Relevance of SARS-CoV-2 related factors ACE2 and TMPRSS2 expressions in gastrointestinal tissue with pathogenesis of digestive symptoms, diabetes-associated mortality, and disease recurrence in COVID-19 patients, Med Hypotheses, 144, 10.1016/j.mehy.2020.110271 Young, 2020, Endocrine aspects of ACE2 regulation: RAAS, steroid hormones and SARS-CoV-2, J Endocrinol, 247, R45, 10.1530/JOE-20-0260 Fang, 2020, Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?, Lancet Respir Med, 8, e21, 10.1016/S2213-2600(20)30116-8 Horby, 2021, Dexamethasone in hospitalized patients with COVID-19, N Engl J Med, 384, 693, 10.1056/NEJMoa2021436 Esguerra, 2020, Glucocorticoid induces human beta cell dysfunction by involving riborepressor GAS5 LincRNA, Mol Metab, 32, 160, 10.1016/j.molmet.2019.12.012 Grover, 2021, A systematic review and meta-analysis to evaluate the clinical outcomes in COVID-19 patients on angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, Eur Heart J Cardiovasc Pharmacother, 7, 148, 10.1093/ehjcvp/pvaa064 Lei, 2020, Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig, Nat Commun, 11, 10.1038/s41467-020-16048-4 Bouhanick, 2021, DPP-4 inhibitors and severe course of illness in patients with COVID-19, Therapie, 76, 359, 10.1016/j.therap.2021.01.051 Samuel, 2021, Therapeutic potential of metformin in COVID-19: reasoning for its protective role, Trends Microbiol, 10.1016/j.tim.2021.03.004 Khunti, 2021, Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England, Lancet Diabetes Endocrinol, 9, 293, 10.1016/S2213-8587(21)00050-4 Katsiki, 2020, Anti-inflammatory properties of antidiabetic drugs: a “promised land” in the COVID-19 era?, J Diabetes Complications, 34, 10.1016/j.jdiacomp.2020.107723 Nohara, 2020, Intratracheal GLP-1 receptor agonist treatment up-regulates mucin via p38 and exacerbates emphysematous phenotype in mucus hypersecretory obstructive lung diseases, Biochem Biophys Res Commun, 524, 332, 10.1016/j.bbrc.2020.01.081 Pal, 2021, Dipeptidyl peptidase-4 inhibitor use and mortality in COVID-19 patients with diabetes mellitus: an updated systematic review and meta-analysis, Ther Adv Endocrinol Metab, 12, 10.1177/2042018821996482 Rhee, 2021, Effects of a DPP-4 inhibitor and RAS blockade on clinical outcomes of patients with diabetes and COVID-19, Diabetes Metab J, 45, 251, 10.4093/dmj.2020.0206 Stumpf, 2021, Humoral and cellular immunity to SARS-CoV-2 vaccination in renal transplant versus dialysis patients: a prospective, multicenter observational study using mRNA-1273 or BNT162b2 mRNA vaccine, Lancet Reg Health Eur, 10.1016/j.lanepe.2021.100178 Dandona, 2021, Diabetes, obesity, COVID-19, Insulin, and other antidiabetes drugs, Diabetes Care, 44, 1929, 10.2337/dci21-0003 Yu, 2021, Insulin treatment is associated with increased mortality in patients with COVID-19 and type 2 diabetes, Cell Metab, 33, 65, 10.1016/j.cmet.2020.11.014 Mancia, 2020, Renin-angiotensin-aldosterone system blockers and the risk of COVID-19, N Engl J Med, 382, 2431, 10.1056/NEJMoa2006923 Mehta, 2020, Association of use of angiotensin-converting enzyme inhibitors and angiotensin ii receptor blockers with testing positive for coronavirus disease 2019 (COVID-19), JAMA Cardiol, 5, 1020, 10.1001/jamacardio.2020.1855 Zhang, 2020, Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19, Circ Res, 126, 1671, 10.1161/CIRCRESAHA.120.317134 Villard, 2020, The plasmatic aldosterone and c-reactive protein levels, and the severity of COVID-19: the Dyhor-19 study, J Clin Med, 9, 10.3390/jcm9072315 Hoffmann, 2020, SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor, Cell, 181, 271, 10.1016/j.cell.2020.02.052 Walls, 2020, Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein, Cell, 181, 281, 10.1016/j.cell.2020.02.058 Davies, 2021, Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England, Science, 372, 10.1126/science.abg3055 Faria, 2021, Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil, Science, 372, 815, 10.1126/science.abh2644 Leung, 2021, Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom, October to November 2020, Euro Surveill, 26, 10.2807/1560-7917.ES.2020.26.1.2002106 Khan, 2021, Higher infectivity of the SARS-CoV-2 new variants is associated with K417N/T, E484K, and N501Y mutants: an insight from structural data, J Cell Physiol, 236, 7045, 10.1002/jcp.30367 Alai, 2021, Pan-India novel coronavirus SARS-CoV-2 genomics and global diversity analysis in spike protein, Heliyon, 7, 10.1016/j.heliyon.2021.e06564 Lan, 2020, Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor, Nature, 581, 215, 10.1038/s41586-020-2180-5 Cantuti-Castelvetri, 2020, Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity, Science, 370, 856, 10.1126/science.abd2985 Wei, 2021, Genome-wide CRISPR screens reveal host factors critical for SARS-CoV-2 infection, Cell, 184, 76, 10.1016/j.cell.2020.10.028 Karki, 2021, Synergism of TNF-α and IFN-γ triggers inflammatory cell death, tissue damage, and mortality in SARS-CoV-2 infection and cytokine shock syndromes, Cell, 184, 149, 10.1016/j.cell.2020.11.025 Nakamura, 2020, Serum levels of receptor-interacting protein kinase-3 in patients with COVID-19, Crit Care, 24, 484, 10.1186/s13054-020-03209-6 Linkermann, 2014, Regulated cell death and inflammation: an auto-amplification loop causes organ failure, Nat Rev Immunol, 14, 759, 10.1038/nri3743 Li, 2020, The MERS-CoV Receptor DPP4 as a candidate binding target of the SARS-CoV-2 spike, iScience, 23, 10.1016/j.isci.2020.101400 Lambeir, 2003, Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV, Crit Rev Clin Lab Sci, 40, 209, 10.1080/713609354 Mulvihill, 2014, Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors, Endocr Rev, 35, 992, 10.1210/er.2014-1035 Drucker, 2020, Coronavirus Infections and type 2 diabetes-shared pathways with therapeutic implications, Endocr Rev, 41, 10.1210/endrev/bnaa011 Seidu, 2020, The impact of obesity on severe disease and mortality in people with SARS-CoV-2: a systematic review and meta-analysis, Endocrinol Diabetes Metab, 4 Ayres, 2020, A metabolic handbook for the COVID-19 pandemic, Nat Metab, 2, 572, 10.1038/s42255-020-0237-2 Stefan, 2020, Causes, consequences, and treatment of metabolically unhealthy fat distribution, Lancet Diabetes Endocrinol, 8, 616, 10.1016/S2213-8587(20)30110-8 Akhmerov, 2020, COVID-19 and the heart, Circ Res, 126, 1443, 10.1161/CIRCRESAHA.120.317055 Avula, 2020, COVID-19 presenting as stroke, Brain Behav Immun, 87, 115, 10.1016/j.bbi.2020.04.077 Boucher, 2014, Insulin receptor signaling in normal and insulin-resistant states, Cold Spring Harb Perspect Biol, 6, 10.1101/cshperspect.a009191 Amin, 2019, How the association between obesity and inflammation may lead to insulin resistance and cancer, Diabetes Metab Syndr, 13, 1213, 10.1016/j.dsx.2019.01.041 Lauterbach, 2017, Macrophage function in obesity-induced inflammation and insulin resistance, Pflugers Arch, 469, 385, 10.1007/s00424-017-1955-5 Santos, 2021, Diabetes, obesity, and insulin resistance in COVID-19: molecular interrelationship and therapeutic implications, Diabetol Metab Syndr, 13, 23, 10.1186/s13098-021-00639-2 Sindhu, 2015, Obesity is a positive modulator of IL-6R and IL-6 expression in the subcutaneous adipose tissue: significance for metabolic inflammation, PLoS One, 10, 10.1371/journal.pone.0133494 Esser, 2014, Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes, Diabetes Res Clin Pract, 105, 141, 10.1016/j.diabres.2014.04.006 Schwarz, 2018, Blood sugar regulation for cardiovascular health promotion and disease prevention: JACC health promotion series, J Am Coll Cardiol, 72, 1829, 10.1016/j.jacc.2018.07.081 Marx, 1998, Regulation of adrenocortical function by cytokines–relevance for immune-endocrine interaction, Horm Metab Res, 30, 416, 10.1055/s-2007-978907 Steenblock, 2020, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the neuroendocrine stress axis, Mol Psychiatry, 25, 1611, 10.1038/s41380-020-0758-9 Ramakrishnan, 2021, Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial, Lancet Respir Med, 9, 763, 10.1016/S2213-2600(21)00160-0 Isidori, 2020, Use of glucocorticoids in patients with adrenal insufficiency and COVID-19 infection, Lancet Diabetes Endocrinol, 8, 472, 10.1016/S2213-8587(20)30149-2 Conti, 2020, Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies, J Biol Regul Homeost Agents, 34, 327 Alsadhan, 2020, Diabetic ketoacidosis precipitated by Coronavirus disease 2019 infection: case series, Curr Ther Res Clin Exp, 93, 10.1016/j.curtheres.2020.100609 Heaney, 2020, Newly diagnosed diabetes and diabetic ketoacidosis precipitated by COVID-19 infection, Am J Emerg Med, 38, 2491e3, 10.1016/j.ajem.2020.05.114 Hollstein, 2020, Autoantibody-negative insulin-dependent diabetes mellitus after SARS-CoV-2 infection: a case report, Nat Metab, 2, 1021, 10.1038/s42255-020-00281-8 Li, 2020, COVID-19 infection may cause ketosis and ketoacidosis, Diabetes Obes Metab, 22, 1935, 10.1111/dom.14057 Montefusco, 2021, Acute and long-term disruption of glycometabolic control after SARS-CoV-2 infection, Nat Metab, 3, 774, 10.1038/s42255-021-00407-6 Naguib, 2020, New onset diabetes with diabetic ketoacidosis in a child with multisystem inflammatory syndrome due to COVID-19, J Pediatr Endocrinol Metab, 34, 147, 10.1515/jpem-2020-0426 Rubino, 2020, New-onset diabetes in COVID-19, N Engl J Med, 383, 789, 10.1056/NEJMc2018688 Kamrath, 2020, Ketoacidosis in children and adolescents with newly diagnosed type 1 diabetes during the COVID-19 pandemic in Germany, JAMA, 324, 801, 10.1001/jama.2020.13445 Salmi, 2021, New-onset type 1 diabetes in Finnish children during the COVID-19 pandemic, Arch Dis Child Kumaran, 2020, Coronavirus disease-19 (COVID-19) associated with acute necrotising pancreatitis (ANP), BMJ Case Rep, 13, 10.1136/bcr-2020-237903 Accili, 2021, Can COVID-19 cause diabetes?, Nat Metab, 3, 123, 10.1038/s42255-020-00339-7 Bailey, 2021, Adhering to COVID-19 health guidelines: examining demographic and psychological predictors of adherence, Appl Psychol Health Well-Being, 10.1111/aphw.12284 Pal, 2021, COVID-19 vaccination in patients with diabetes mellitus: current concepts, uncertainties and challenges, Diabetes Metab Syndr, 15, 505, 10.1016/j.dsx.2021.02.026 McGovern, 2021, The disproportionate excess mortality risk of COVID-19 in younger people with diabetes warrants vaccination prioritisation, Diabetologia, 64, 1184, 10.1007/s00125-021-05404-8 Müller, 2013, The European perspective of diabetes prevention: the need for individualization of diabetes prevention, J Endocrinol Invest, 36, 352, 10.1007/BF03347104 Quinn, 2021, Use of MyDesmond digital education programme to support self-management in people with type 2 diabetes during the COVID-19 pandemic, Diabet Med, 38, 10.1111/dme.14469 Rogers, 2020, Diabetes-related amputations: a pandemic within a pandemic, J Am Podiatr Med Assoc Chudasama, 2020, Impact of COVID-19 on routine care for chronic diseases: a global survey of views from healthcare professionals, Diabetes Metab Syndr, 14, 965, 10.1016/j.dsx.2020.06.042 Rowlands, 2021, The impact of COVID-19 restrictions on accelerometer-assessed physical activity and sleep in individuals with type 2 diabetes, Diabet Med, 10.1111/dme.14549 Gregg, 2021, Diabetes and COVID-19: population impact 18 months into the pandemic, Diabetes Care, 44, 1916, 10.2337/dci21-0001 McGurnaghan, 2021, Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland, Lancet Diabetes Endocrinol, 9, 82, 10.1016/S2213-8587(20)30405-8 Petrie, 2021, A post COVID-19 ‘Marshall Plan’ for type 2 diabetes, Diabet Med, 38, 10.1111/dme.14439 Cyranka, 2021, Psychological crisis intervention for COVID-19 lockdown stress in patients with type 1 diabetes mellitus: survey study and qualitative analysis, JMIR Ment Health, 8, 10.2196/28097 Ruissen, 2021, Increased stress, weight gain and less exercise in relation to glycemic control in people with type 1 and type 2 diabetes during the COVID-19 pandemic, BMJ Open Diabetes Res Care, 9, 10.1136/bmjdrc-2020-002035 Ruberti, 2021, Stress and physical inactivity: two explosive ingredients for the heart in COVID-19 pandemic times, Curr Cardiol Rev, 10.2174/1573403X17666210126103204 Ceriello, 2021, Pharmacological management of COVID-19 in type 2 diabetes, J Diabetes Complications, 35, 10.1016/j.jdiacomp.2021.107927 Kosiborod, 2021, Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet Diabetes Endocrinol, 9, 586, 10.1016/S2213-8587(21)00180-7 Cariou, 2021, Phenotypic characteristics and prognosis of newly diagnosed diabetes in hospitalized patients with COVID-19: results from the CORONADO study, Diabetes Res Clin Pract, 175, 10.1016/j.diabres.2021.108695 Noh, 2021, Association between DPP-4 inhibitors and COVID-19-related outcomes among patients with type 2 diabetes, Diabetes Care, 44, e64, 10.2337/dc20-1824 Solerte, 2020, Sitagliptin treatment at the time of hospitalization was associated with reduced mortality in patients with type 2 diabetes and covid-19: a multicenter, case-control, retrospective, observational study, Diabetes Care, 43, 2999, 10.2337/dc20-1521 Kow, 2021, Mortality risk with preadmission metformin use in patients with COVID-19 and diabetes: a meta-analysis, J Med Virol, 93, 695, 10.1002/jmv.26498 Scheen, 2020, Metformin and COVID-19: from cellular mechanisms to reduced mortality, Diabetes Metab, 46, 423, 10.1016/j.diabet.2020.07.006 Cheng, 2020, Metformin is associated with higher incidence of acidosis, but not mortality, in individuals with COVID-19 and pre-existing type 2 diabetes, Cell Metab, 32, 537, 10.1016/j.cmet.2020.08.013 Group, 2021, Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial, Lancet, 397, 1637, 10.1016/S0140-6736(21)00676-0 Castañeda, 2019, Rapid beneficial effect of the IL-6 receptor blockade on insulin resistance and insulin sensitivity in non-diabetic patients with rheumatoid arthritis, Clin Exp Rheumatol, 37, 465 Marfella, 2020, Negative impact of hyperglycaemia on tocilizumab therapy in COVID-19 patients, Diabetes Metab, 46, 403, 10.1016/j.diabet.2020.05.005 Katulanda, 2020, Prevention and management of COVID-19 among patients with diabetes: an appraisal of the literature, Diabetologia, 63, 1440, 10.1007/s00125-020-05164-x Sterne, 2020, Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: meta-analysis A, JAMA, 324, 1330, 10.1001/jama.2020.17023 Perez, 2014, Glucocorticoid-induced hyperglycemia, J Diabetes, 6, 9, 10.1111/1753-0407.12090 Zhu, 2020, Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes, Cell Metab, 31, 1068, 10.1016/j.cmet.2020.04.021 Klonoff, 2021, Association between achieving inpatient glycemic control and clinical outcomes in hospitalized patients with COVID-19: a multicenter, retrospective hospital-based analysis, Diabetes Care, 44, 578, 10.2337/dc20-1857 Lu, 2021, Time in range in relation to all-cause and cardiovascular mortality in patients with type 2 diabetes: a prospective cohort study, Diabetes Care, 44, 549, 10.2337/dc20-1862 Wu, 2017, Altered lipid metabolism in recovered SARS patients twelve years after infection, Sci Rep, 7 Yang, 2010, Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes, Acta Diabetol, 47, 193, 10.1007/s00592-009-0109-4 Moldofsky, 2011, Chronic widespread musculoskeletal pain, fatigue, depression and disordered sleep in chronic post-SARS syndrome; a case-controlled study, BMC Neurol, 11, 37, 10.1186/1471-2377-11-37 Wostyn, 2021, COVID-19 and chronic fatigue syndrome: is the worst yet to come?, Med Hypotheses, 146, 10.1016/j.mehy.2020.110469 Al-Aly, 2021, High-dimensional characterization of post-acute sequelae of COVID-19, Nature, 594, 259, 10.1038/s41586-021-03553-9 Barker-Davies, 2020, The Stanford Hall consensus statement for post-COVID-19 rehabilitation, Br J Sports Med, 54, 949, 10.1136/bjsports-2020-102596 Berger, 2019, The adrenal gland in stress – adaptation on a cellular level, J Steroid Biochem Mol Biol, 190, 198, 10.1016/j.jsbmb.2019.04.006 Rohr, 2021, Experiences, opinions and expectations of health care providers towards an intensive care unit follow-up clinic: Qualitative study and online survey, Intensive Crit Care Nurs, 10.1016/j.iccn.2021.103084 Steinbrink, 2021, Mucormycosis, Infect Dis Clin North Am, 35, 435, 10.1016/j.idc.2021.03.009 Sharma, 2021, Post coronavirus disease mucormycosis: a deadly addition to the pandemic spectrum, J Laryngol Otol, 135, 442, 10.1017/S0022215121000992 Khunti, 2021, Long COVID – metabolic risk factors and novel therapeutic management, Nat Rev Endocrinol, 17, 379, 10.1038/s41574-021-00495-0 Ayoubkhani, 2021, Post-COVID syndrome in individuals admitted to hospital with COVID-19: retrospective cohort study, BMJ, 372, n693, 10.1136/bmj.n693 Correr, 2020, Prevalence of people at risk of developing type 2 diabetes mellitus and the involvement of community pharmacies in a national screening campaign: a pioneer action in Brazil, Diabetol Metab Syndr, 12, 89, 10.1186/s13098-020-00593-5 Mehta, 2009, Diabetes mellitus in India: the modern scourge, Med J Armed Forces India, 65, 50, 10.1016/S0377-1237(09)80056-7 Satman, 2013, Twelve-year trends in the prevalence and risk factors of diabetes and prediabetes in Turkish adults, Eur J Epidemiol, 28, 169, 10.1007/s10654-013-9771-5 Soy Timpel, 2019, What should governments be doing to prevent diabetes throughout the life course?, Diabetologia, 62, 1842, 10.1007/s00125-019-4941-y Jose, 2021, Digital health surveillance strategies for management of coronavirus disease 2019, Mayo Clin Proc Innov Qual Outcomes, 5, 109, 10.1016/j.mayocpiqo.2020.12.004 Deckert, 2021, Effectiveness and cost-effectiveness of four different strategies for SARS-CoV-2 surveillance in the general population (CoV-Surv Study): a structured summary of a study protocol for a cluster-randomised, two-factorial controlled trial, Trials, 22, 39, 10.1186/s13063-020-04982-z Ogilvie, 1937, A quantitative estimation of the pancreatic islet tissue1, QJM, 6, 287 Jacob, 2021, Change in glucose-lowering medication regimens in individuals with type 2 diabetes mellitus during the COVID-19 pandemic in Germany, Diabetes Obes Metab, 23, 910, 10.1111/dom.14293 Chan, 2021, The Lancet Commission on diabetes: using data to transform diabetes care and patient lives, Lancet, 396, 2019, 10.1016/S0140-6736(20)32374-6